Latest Prilenia Therapeutics News & Updates
See the latest news and media coverage for Prilenia Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Clinical-stage biotech developing neurodegenerative disease treatments
prilenia.com- Headquarters
- Boston, United States
- Founded year
- 2018
- Company type
- Private company
- Number of employees
- 10–70
Last updated
Latest news about Prilenia Therapeutics
In short: Prilenia Therapeutics advanced its Phase 3 trial for ALS and appointed a new CFO following a regulatory setback in the European Union.
Company announcements
-
Prilenia joins American Biotech Innovation Alliance as founding member
Eric Litjens emphasizes harnessing biotech innovation for economy, healthcare leadership, and patient outcomes in rare neurodegenerative diseases like ALS and Huntington's.
-
Prilenia appoints Elisabeth Leiderman as CFO
She brings over 20 years of finance and biotech experience, including fundraising and strategic transactions. The appointment supports Phase 3 studies for HD and ALS.
-
Prilenia announces first enrollment in PREVAiLS Phase 3 ALS study
The 500-participant trial evaluates pridopidine's efficacy in slowing progression for early, rapidly progressive ALS patients across 13 countries.
-
Prilenia Therapeutics presents Phase 3 PREVAiLS study design
Dr. Angela Genge presented at the 2026 Muscular Dystrophy Association Conference. The global study of pridopidine in early ALS enrolls soon in Canada.
Media coverage
-
Prilenia Appoints Dr. Elisabeth Leiderman as Chief Financial Officer
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington's disease (HD) and...
-
Breakthrough ALS study launches as drug aims to slow disease progression | Jammin 99.9 (WKXB FM)
The “PREVAiLS” study, which will review the investigational drug pridopidine as a potential ALS treatment, has already enrolled its first participant, according to a press...
-
Prilenia and Ferrer enrol first participant in PREVAiLS Phase III trial
Prilenia Therapeutics and Ferrer have enrolled the first participant in the Phase III PREVAiLS trial assessing pridopidine in early ALS.
-
JAMA Neurology Publishes Results from PARADIGM Phase 2b Trial of PrimeC in ALS Demonstrating Meaningful Clinical Outcomes and Biological Activity
/PRNewswire/ -- NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) ("NeuroSense"), a late-stage clinical biotechnology company focused on developing disease-modifying...
Track Prilenia Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Prilenia Therapeutics competitors & trending companies
Browse news for competitors to Prilenia Therapeutics and other trending companies.
Clene
Neurizon Therapeutics
Annexon Biosciences
Revalesio
Acelot
Herantis Pharma
Mitochon Pharmaceuticals
Verge Genomics
NeuroSense Therapeutics
Harness Therapeutics
Aquilus Pharmaceuticals
Aperture Therapeutics
Raya
Origami Therapeutics
Pit
Davis AI
Qutwo
DigiPowerX
Penguin Solutions
Sterling Infrastructure
KIOXIA Corporation
Subquadratic
Tibber
IREN
A24
Hitachi Energy
Ouster
Ormat Technologies
Fabrinet
AOI
WidePoint
Filtronic
Mirum Pharmaceuticals
Capstone Green Energy
AXT
POET Technologies